158 related articles for article (PubMed ID: 36578946)
1. Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients.
Nguyen HT; Nguyen TV; Nguyen Hoang VA; Tran DH; Le Trinh NA; Le MT; Nguyen Tran TA; Pham TH; Dinh TC; Nguyen TS; Nguyen The KC; Mai H; Chu MT; Pham DH; Nguyen XC; Ngo Ha TM; Nguyen DS; Nguyen DQ; Lu YT; Do Thi TT; Truong DK; Nguyen QT; Nguyen HN; Giang H; Tu LN
Front Oncol; 2022; 12():1069296. PubMed ID: 36578946
[TBL] [Abstract][Full Text] [Related]
2. Genetic landscape and personalized tracking of tumor mutations in Vietnamese women with breast cancer.
Nguyen Hoang VA; Nguyen ST; Nguyen TV; Pham TH; Doan PL; Nguyen Thi NT; Nguyen ML; Dinh TC; Pham DH; Nguyen NM; Nguyen DS; Nguyen DQ; Lu YT; Do TTT; Truong DK; Phan MD; Nguyen HN; Giang H; Tu LN
Mol Oncol; 2023 Apr; 17(4):598-610. PubMed ID: 36495126
[TBL] [Abstract][Full Text] [Related]
3. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
[TBL] [Abstract][Full Text] [Related]
4. Sequencing paired tumor DNA and white blood cells improves circulating tumor DNA tracking and detects pathogenic germline variants in localized colon cancer.
Gimeno-Valiente F; Martín-Arana J; Tébar-Martínez R; Gambardella V; Martínez-Ciarpaglini C; García-Micó B; Martínez-Castedo B; Palomar B; García-Bartolomé M; Seguí V; Huerta M; Moro-Valdezate D; Pla-Martí V; Pérez-Santiago L; Roselló S; Roda D; Cervantes A; Tarazona N
ESMO Open; 2023 Dec; 8(6):102051. PubMed ID: 37951129
[TBL] [Abstract][Full Text] [Related]
5. The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer.
Cai J; Jiang H; Li S; Yan X; Wang M; Li N; Zhu C; Dong H; Wang D; Xu Y; Xie H; Wu S; Lou J; Zhao J; Li Q
Front Oncol; 2021; 11():751106. PubMed ID: 35273907
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy.
Yang W; Zou J; Li Y; Liu R; Yan Z; Chen S; Zhao X; Guo W; Huang M; Li W; Zhu X; Chen Z
Front Oncol; 2022; 12():830816. PubMed ID: 35280779
[TBL] [Abstract][Full Text] [Related]
7. ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine.
Pellini B; Pejovic N; Feng W; Earland N; Harris PK; Usmani A; Szymanski JJ; Qaium F; Mudd J; Petty M; Jiang Y; Singh A; Maher CA; Henke LE; Park H; Ciorba MA; Kim H; Mutch MG; Pedersen KS; Tan BR; Hawkins WG; Fields RC; Chaudhuri AA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250420
[TBL] [Abstract][Full Text] [Related]
8. Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay.
Powles T; Young A; Nimeiri H; Madison RW; Fine A; Zollinger DR; Huang Y; Xu C; Gjoerup OV; Aushev VN; Wu HT; Aleshin A; Carter C; Davarpanah N; Degaonkar V; Gupta P; Mariathasan S; Schleifman E; Assaf ZJ; Oxnard G; Hegde PS
Front Oncol; 2023; 13():1221718. PubMed ID: 37601688
[TBL] [Abstract][Full Text] [Related]
9. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
10. Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients.
Chan HT; Nagayama S; Otaki M; Chin YM; Fukunaga Y; Ueno M; Nakamura Y; Low SK
Front Oncol; 2022; 12():1055968. PubMed ID: 36776372
[TBL] [Abstract][Full Text] [Related]
11. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer.
Parikh AR; Van Seventer EE; Siravegna G; Hartwig AV; Jaimovich A; He Y; Kanter K; Fish MG; Fosbenner KD; Miao B; Phillips S; Carmichael JH; Sharma N; Jarnagin J; Baiev I; Shah YS; Fetter IJ; Shahzade HA; Allen JN; Blaszkowsky LS; Clark JW; Dubois JS; Franses JW; Giantonio BJ; Goyal L; Klempner SJ; Nipp RD; Roeland EJ; Ryan DP; Weekes CD; Wo JY; Hong TS; Bordeianou L; Ferrone CR; Qadan M; Kunitake H; Berger D; Ricciardi R; Cusack JC; Raymond VM; Talasaz A; Boland GM; Corcoran RB
Clin Cancer Res; 2021 Oct; 27(20):5586-5594. PubMed ID: 33926918
[TBL] [Abstract][Full Text] [Related]
12. Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer.
Wang W; Huang Y; Kong J; Lu L; Liao Q; Zhu J; Wang T; Yan L; Dai M; Chen Z; You J
Clin Transl Oncol; 2024 May; ():. PubMed ID: 38777950
[TBL] [Abstract][Full Text] [Related]
13. Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy.
Li G; Pavlick D; Chung JH; Bauer T; Tan BA; Peguero J; Ward P; Kallab A; Bufill J; Hoffman A; Sadiq A; Edenfield J; He J; Cooke M; Hughes J; Forcier B; Nahas M; Stephens P; Ali SM; Schrock AB; Ross JS; Miller VA; Gregg JP
J Gastrointest Oncol; 2019 Oct; 10(5):831-840. PubMed ID: 31602320
[TBL] [Abstract][Full Text] [Related]
14. Postoperative Circulating Tumor DNA Can Predict High Risk Patients with Colorectal Cancer Based on Next-Generation Sequencing.
Lee CS; Kim HS; Schageman J; Lee IK; Kim M; Kim Y
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439344
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
16. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics.
Choi IS; Kato S; Fanta PT; Leichman L; Okamura R; Raymond VM; Lanman RB; Lippman SM; Kurzrock R
Mol Cancer Ther; 2019 Oct; 18(10):1852-1862. PubMed ID: 31320401
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.
Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W
J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor DNA analysis predicts recurrence and avoids unnecessary adjuvant chemotherapy in I-IV colorectal cancer.
Fan W; Xia Z; Chen R; Lin D; Li F; Zheng Y; Luo J; Xiong Y; Yu P; Gao W; Gong Y; Zhang F; Zhang S; Li L
Ther Adv Med Oncol; 2024; 16():17588359231220607. PubMed ID: 38282662
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
